Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span
Open accessAbstract
BACKGROUND: Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder with loss of function mutations of lipoprotein lipase resulting in hypertriglyceridemia and accumulation of chylomicrons in plasma, often leading to acute pancreatitis. The mainstay of treatment is a specialized very-low-fat diet. Even adhering to the diet, some patients may experience high triglycerides and pancreatitis. There currently are no comprehensive dietary guidelines. OBJECTIVE: To report best practices and develop comprehensive dietary guidelines for nutrition therapy in patients with FCS. METHODS: Registered dietitian nutritionists (RDNs) convened to develop this report based on experience treating patients with FCS and a review of current literature on the topic. One author provided a patient perspective of living with FCS. RESULTS: This report provides guidelines and rationales for nutrition therapy associated with FCS across the life span. The top global guidelines are to (1) limit fat to <15 to 20 g per day (<10%-15% of total daily energy intake); (2) meet recommendations for essential fatty acids: α-linolenic acid and linoleic acid; (3) choose complex carbohydrate foods while limiting simple and refined carbohydrate foods; (4) supplement with fat-soluble vitamins, minerals, and medium-chain triglyceride oil, as needed; (5) adjust calories for weight management. Recommended foods include vegetables, whole grains, legumes, lean protein foods, fruits in limited amounts, and fat-free milk products without added sugars. Foods to avoid include alcohol and products high in sugar. CONCLUSIONS: These patient-centered nutrition guidelines provide guidance to help patients adhere to the recommended diet and optimize nutritional needs.
AI snapshot
Written from the paper’s full text.
TL;DR
This expert-panel article provides patient-centered, lifespan dietary guidelines for familial chylomicronemia syndrome (FCS), centered on a very-low-fat diet and multidisciplinary care. It synthesizes literature and clinical experience because no randomized trials exist for this rare disorder.
Key findings
- The panel recommends a very-low-fat diet of less than 15–20 g fat per day or less than 10%–15% of total daily calories, with fat distributed throughout the day; the target is to maintain triglycerides below 1000 mg/dL, and below 500 mg/dL during pregnancy.
- Patients should meet essential fatty acid needs at 2%–4% of daily calories, may use medium-chain triglyceride oil to add calories, limit total carbohydrate to no more than 60% of daily calories, avoid added sugars and alcohol, and monitor/supplement fat-soluble vitamins A, D, E, and K as needed.
- FCS affects 1 to 2 per million people; triglyceride levels may range from 1500 to 15,000 mg/dL or higher, acute pancreatitis was reported by 42% of patients with FCS, and acute pancreatitis risk increases by 4% for every 100 mg/dL rise in triglycerides.
- Patients report visiting at least 5 physicians (range 1–30) before diagnosis; psychosocial burden includes 22% reporting depressive episodes and only 22% able to sustain full-time employment in an interim analysis.
Methods
- Design: expert-panel best-practice guidelines developed by registered dietitian nutritionists (RDNs) with experience treating FCS, incorporating the perspective of one patient with FCS.
- Data/sample: review of current clinical and scientific literature plus personal clinical experience; no randomized controlled trials or meta-analyses were available because of the rarity of FCS.
- Analysis: consensus recommendations organized across the life span and special populations, including pediatrics, pregnancy, diabetes, acute pancreatitis, and chronic pancreatitis.
Limitations
- Stated: the guidelines are based on a literature review and expert opinion of RDNs; owing to low FCS prevalence, there are no randomized controlled clinical trials or robust data sets, so recommendations rest on limited observations and clinical experience.
- Evident from the text: no formal systematic review or prospective validation is described; the patient perspective comes from a single patient; some recommendations are generalized from hypertriglyceridemia rather than FCS-specific (e.g., physical activity); and the work was funded by Akcea Therapeutics, including writing support.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 79 cited sources checked · 0 supported · 0 flagged
- Premisecitation§ Introduction
Effectiveness of omega-3 fatty acids, routinely used in pharmacologic doses for treatment of severe HTG, has been inconsistent in patients with FCS.
“Effectiveness of omega-3 fatty acids, routinely used in pharmacologic doses for treatment of severe HTG, has been inconsistent in patients with FCS.3,[16][17][18]20”
Quote in the paperSubstantial claim0 of 6 sources checked- cites [3] Brahm, 2015, Chylomicronaemia–current diagnosis and future therapies, Nat Rev Endocrinol source
Not checked in the free run.
- cites [16] Helk, 2016, Effects of two therapeutic dietary regimens on primary chylomicronemia in paediatric age: a retrospective data analysis, Eur J Clin Nutr source
Not checked in the free run.
- cites [17] Yuan, 2007, Hypertriglyceridemia: its etiology, effects and treatment, CMAJ source
Not checked in the free run.
- cites [18] Connor, 1993, N-3 fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients, Ann NY Acad Sci source
Not checked in the free run.
- cites [19] Pschierer, 1995, Primary chylomicronemia in patients with severe familial hypertriglyceridemia responds to long-term treatment with (n-3) fatty acids, J Nutr source
Not checked in the free run.
- cites [20] Brunzell, 2007, Hypertriglyceridemia, N Engl J Med source
Not checked in the free run.
- Premisecitation§ Introduction
Even when patients adhere to the very-low-fat diet and are monitored by a registered dietitian nutritionist, TG levels may remain dangerously high.
“Even when patients adhere to the very-low-fat diet and are monitored by a registered dietitian nutritionist (RDN), TG levels may remain dangerously high.3,20,21”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [3] Brahm, 2015, Chylomicronaemia–current diagnosis and future therapies, Nat Rev Endocrinol source
Not checked in the free run.
- cites [20] Brunzell, 2007, Hypertriglyceridemia, N Engl J Med source
Not checked in the free run.
- cites [21] Bryant, 2013, Lessons learned from the clinical development and market authorization of Glybera, Hum Gene Ther Clin Dev source
Not checked in the free run.
- Premisecitation§ Introduction
A delay in diagnosis may place patients at an increased risk for acute pancreatitis.
“A delay in diagnosis may place patients at an increased risk for acute pancreatitis.11”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [11] Berglund, 2012, Endocrine society. Evaluation and treatment of hypertriglyceridemia: An Endocrine Society clinical practice guideline, J Clin Endocrinol Metab source
Not checked in the free run.
- Premisecitation§ Introduction
A lack of familiarity with FCS among health care providers may be one reason patients with FCS report visiting at least 5 physicians (range 1-30) before receiving a diagnosis of FCS.
“A lack of familiarity with FCS among health care providers may be one reason patients with FCS report visiting at least 5 physicians (range 1-30) before receiving a diagnosis of FCS. 13”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [13] Davidson, 2017, The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study, Expert Rev Cardiovasc Ther source
Not checked in the free run.
- Premisecitation§ Dietary guidelines for all patients with FCS
People with FCS cannot metabolize chylomicron-associated TGs.
“People with FCS cannot metabolize chylomicron-associated TGs. 5”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [5] Hegele, 2014, The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis and management, Lancet Diabetes Endocrinol source
Not checked in the free run.
- Interpretationreasoning§ Introduction
No comprehensive best practice dietary guidelines across the life span exist.
“No comprehensive best practice dietary guidelines across the life span exist.”
Quote in the paperSubstantial claim - Premisecitation§ Introduction
Currently, the only published guidelines for managing diet restrictions in patients with FCS are for infants, children, and adolescents.
“Currently, the only published guidelines for managing diet restrictions in patients with FCS are for infants, children, and adolescents.22”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [22] Williams, 2016, Editorial commentary: Dietary management of familial chylomicronemia syndrome, J Clin Lipidol source
Not checked in the free run.
- Premisecitation§ Special populations Pregnancy and FCS
This is caused by increased liver synthesis of TGs in response to elevated estrogen levels.
“This is caused by increased liver synthesis of TGs in response to elevated estrogen levels.47”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [47] Bolla, 2012, Chylomicronemia syndrome in pregnancy: a case report of an acute necrotizing pancreatitis, Geburtshilfe Frauenheilkd source
Not checked in the free run.
- Premisecitation§ Fat
The Food and Agriculture Organization of the United Nations and the World Health Organization set the minimum intake of LA and ALA to prevent deficiency symptoms in adults as 2.5% and 0.5% of daily energy intake, respectively.
“However, the Food and Agriculture Organization of the United Nations and the World Health Organization set the minimum intake of LA and ALA to prevent deficiency symptoms in adults as 2.5% and 0.5% of daily energy intake, respectively.26”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [26] Elmadfa, 2009, Fats and fatty acid requirements for adults, Ann Nutr Metab source
Not checked in the free run.
- Premisecitation§ Acute pancreatitis
During attacks of acute pancreatitis, early aggressive IV hydration with 250 to 500 mL/h may prevent intravascular volume depletion and pancreatic necrosis.
“During attacks of acute pancreatitis, early aggressive IV hydration with 250 to 500 mL/h may prevent intravascular volume depletion and pancreatic necrosis.50,51”
Quote in the paperSubstantial claim0 of 2 sources checked - Premisecitation§ Fat
MCT oil may be used as a nutritional supplement for patients with FCS because MCT is metabolized through a chylomicron-independent pathway.
“MCT oil may be used as a nutritional supplement for patients with FCS because MCT is metabolized through a chylomicron-independent pathway.21”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [21] Bryant, 2013, Lessons learned from the clinical development and market authorization of Glybera, Hum Gene Ther Clin Dev source
Not checked in the free run.
- Premisecitation§ Conclusions
Patients with other etiologies of HTG who received regular testing to monitor TG levels significantly lowered their TG levels compared with a control group who did not monitor their lipid levels.
“Patients with other etiologies of HTG who received regular testing to monitor TG levels were shown to significantly lower their TG levels compared with the control group who did not monitor their lipid levels.58”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [58] Hauenschild, 2008, Successful long-term treatment of severe hypertriglyceridemia by feedback control with lipid self-monitoring, Ann Nutr Metab source
Not checked in the free run.
- Premisecitation§ Diabetes
Patients with FCS who have experienced multiple episodes of pancreatitis, and may have suffered due to pancreatic damage, may develop type 3c or pancreatogenic diabetes.
“Patients with FCS who have experienced multiple episodes of pancreatitis, and may have suffered due to pancreatic damage, may develop type 3c or pancreatogenic diabetes.49”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [49] Rickels, 2013, Detection, evaluation, and treatment of diabetes mellitus in chornic pancreatitis: recommendations from PancreasFest 2012, Pancreatology source
Not checked in the free run.
- Premisecitation§ Fat
MCTs, including caprylic acid (C8) and capric acid (C10), are hydrolyzed and bound to albumin for travel via the portal vein to the liver where they are oxidized to ketones, thereby bypassing the chylomicron-dependent pathway for fat metabolism.
“MCTs, including caprylic acid (C8) and capric acid (C10), are hydrolyzed and bound to albumin for travel via the portal vein to the liver where they are oxidized to ketones, thereby bypassing the chylomicrondependent pathway for fat metabolism.28”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [28] Ahmad, 2014, Familial chylomicronemia syndrome and response to medium-chain triglyceride therapy in an infant with novel mutations in GPIHBP1, J Clin Lipidol source
Not checked in the free run.
- Premisecitation§ Chronic pancreatitis
Up to 50% or more of patients with FCS that have uncontrolled TG levels develop recurrent acute pancreatitis.
“Up to 50% or more of patients with FCS that have uncontrolled TG levels develop recurrent acute pancreatitis.53”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [53] Gaudet, 2016, Acute pancreatitis is highly prevalent and complications can be fatal in patients with familial chylomicronemia: results from a survey of lipidologists, J Clin Lipidol source
Not checked in the free run.
- Premisecitation§ Fat
Prescription omega-3 fatty acids (up to 4 grams per day) have shown inconsistent effectiveness as a treatment for HTG in patients with FCS.
“Of note, prescription omega-3 fatty acids (up to 4 grams per day) have shown inconsistent effectiveness as a treatment for HTG in patients with FCS.3,[16][17][18][19]”
Quote in the paperNot a substantial claim0 of 5 sources checked- cites [3] Brahm, 2015, Chylomicronaemia–current diagnosis and future therapies, Nat Rev Endocrinol source
Not checked in the free run.
- cites [16] Helk, 2016, Effects of two therapeutic dietary regimens on primary chylomicronemia in paediatric age: a retrospective data analysis, Eur J Clin Nutr source
Not checked in the free run.
- cites [17] Yuan, 2007, Hypertriglyceridemia: its etiology, effects and treatment, CMAJ source
Not checked in the free run.
- cites [18] Connor, 1993, N-3 fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients, Ann NY Acad Sci source
Not checked in the free run.
- cites [19] Pschierer, 1995, Primary chylomicronemia in patients with severe familial hypertriglyceridemia responds to long-term treatment with (n-3) fatty acids, J Nutr source
Not checked in the free run.
- Premisecitation§ Fat
The safety of long-term use of high doses of MCT oil is not established.
“The safety of long-term use of high doses of MCT oil is not established.31,32”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [31] Chamma, 2017, A rich medium-chain triacylglycerol diet benefits adiposity but has adverse effects on the markers of hepatic lipogenesis and beta-oxidation, Food Funct source
Not checked in the free run.
- cites [32] Densupsoontorn, 2014, Fat-soluble vitamins and plasma and erythrocyte membrane fatty acids in chylothorax pediatric patients receiving a medium-chain triglyceride-rich diet, J Clin Biochem Nutr source
Not checked in the free run.
- Premisecitation§ Dietary guidelines for all patients with FCS
The risk of acute pancreatitis increases by 4% for every 100 mg/dL rise in TG.
“The risk of acute pancreatitis increases by 4% for every 100 mg/dL rise in TG. 23”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [23] Murphy, 2013, Hypertriglyceridemia and acute pancreatitis, JAMA Intern Med source
Not checked in the free run.
- Premisecitation§ Fat-soluble vitamin (A, D, E, K) supplementation should be
Prolonged dehydration, which is often accompanied by diarrhea and vomiting, may increase the risk of developing acute pancreatitis.
“Prolonged dehydration, which is often accompanied by diarrhea and vomiting, may increase the risk of developing acute pancreatitis.34,38”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [34] LaRusch, 2014, Pancreatitis overview
Not checked in the free run.
- cites [38] Tenner, 2013, American College of Gastroenterology Guideline: Management of Acute Pancreatitis, Am J Gastroenterol
Not checked in the free run.
- Premisecitation§ Acute pancreatitis
Initiating IV hydration within the first 12 hours of acute pancreatitis onset may prevent further complications.
“Ideally, initiating IV hydration within the first 12 hours of acute pancreatitis onset may prevent further complications.52”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [52] Banks, 2006, Practice guidelines in acute pancreatitis, Am J Gastroenterol source
Not checked in the free run.
- Premisecitation§ Special populations Pregnancy and FCS
Plasma TGs normally rise during pregnancy, especially during the third trimester.
“Plasma TGs normally rise during pregnancy, 45 especially during the third trimester.46”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [45] Warth, 1975, Lipid metabolism in pregnancy. II. Altered lipid composition in intermediage, very low, low and high-density lipoprotein fractions, J Clin Endocrinol Metab source
Not checked in the free run.
- cites [46] Goldberg, 2012, Severe hypertriglyceridemia in pregnancy, J Clin Endocrinol Metab source
Not checked in the free run.
- Premisecitation§ Fat-soluble vitamin (A, D, E, K) supplementation should be
Patients with FCS may be at risk for developing eating disorders, such as bulimia.
“Patients with FCS may be at risk for developing eating disorders, such as bulimia.41”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [41] Gavish, 1987, Bulimia–An underlying behavioral disorder in hyperlipidemic pancreatitis: a prospective multidisciplinary approach, Arch Intern Med source
Not checked in the free run.
- Premisecitation§ Fat-soluble vitamin (A, D, E, K) supplementation should be
Most adults require approximately 35 mL/kg of water daily.
“Most adults require approximately 35 mL/kg of water daily.39”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [39] Institute of Medicine, 2004
Not checked in the free run.
- Premisecitation§ Conclusions
An interim analysis of patients with FCS showed that only 22% were able to sustain full-time employment.
“An interim analysis of patients with FCS showed that only a small percentage of patients (22%) were able to sustain full-time employment.13”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [13] Davidson, 2017, The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study, Expert Rev Cardiovasc Ther source
Not checked in the free run.
- Premisecitation§ Conclusions
Other patients with FCS have reported reduced quality of life due to anxiety, fear, and worry about food and eating, symptoms, and overall health due to FCS.
“Similar results have been reported by other patients with FCS, including reduced quality of life due to anxiety, fear, and worry about food and eating, symptoms, and overall health due to FCS. 13”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [13] Davidson, 2017, The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study, Expert Rev Cardiovasc Ther source
Not checked in the free run.
- Premisecitation§ Conclusions
Twenty-two percent of patients with FCS reported depressive episodes.
“Twenty-two percent of FCS patients reported depressive episodes, and other cognitive symptoms such as impaired memory, difficulty concentrating, fatigue, and weakness.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [13] Davidson, 2017, The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study, Expert Rev Cardiovasc Ther source
Not checked in the free run.
- Interpretationcitation§ Conclusions
The limitations imposed by the very-low-fat diet may negatively impact the overall quality of life and psychosocial well-being of patients with FCS.
“As health care providers, it is important to remember we are treating individuals and asking them to follow a restrictive diet, and the limitations the diet imposes may negatively impact their overall quality of life and psychosocial well-being.13”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [13] Davidson, 2017, The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study, Expert Rev Cardiovasc Ther source
Not checked in the free run.
- Premisecitation§ Conclusions
Dietary counseling enabled patients to better adhere to the low-fat dietary regimen.
“Dietary counseling was attributed to the success of individuals with other conditions on low-fat diets (,15% fat), and dietary counseling enabled patients to better adhere to the low-fat dietary regimen.64”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [64] Link, 2004, Adherence to a low-fat diet in men with prostate cancer, Urology source
Not checked in the free run.
- Premisecitation§ Conclusions
Dietary counseling was attributed to the success of individuals with other conditions on low-fat diets (<15% fat).
“Dietary counseling was attributed to the success of individuals with other conditions on low-fat diets (,15% fat), and dietary counseling enabled patients to better adhere to the low-fat dietary regimen.64”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [64] Link, 2004, Adherence to a low-fat diet in men with prostate cancer, Urology source
Not checked in the free run.
- May combine two claims. 19
- Classified as probably not a substantial claim. 17
May combine two claims.
Premisecitation§ IntroductionOther symptoms of FCS are recurrent pancreatitis, severe abdominal pain ranging from mild to incapacitating (with or without pancreatitis), hepatosplenomegaly, lipemic plasma, eruptive xanthomas, lipemia retinalis, and decreased quality of life.
“Other symptoms of FCS are recurrent pancreatitis, severe abdominal pain ranging from mild to incapacitating (with or without pancreatitis), hepatosplenomegaly, lipemic plasma, eruptive xanthomas, lipemia retinalis, 1,14,15 and decreased quality of life.13”
Quote in the paperNot a substantial claim0 of 4 sources checked- cites [1] Burnett, 1999, Familial lipoprotein lipase deficiency
Not checked in the free run.
- cites [14] Brunzell, 2001, Familial lipoprotein lipase deficiency, apo C-II deficiency and hepatic lipase deficiency
Not checked in the free run.
- cites [15] Ahmad, 2017, Building a better understanding of the burden of disease in familial chylomicronemia syndrome, Expert Rev Clin Pharmacol source
Not checked in the free run.
- cites [13] Davidson, 2017, The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study, Expert Rev Cardiovasc Ther source
Not checked in the free run.
May combine two claims.
Premisecitation§ IntroductionAcute pancreatitis can lead to chronic pancreatitis, signs of exocrine or endocrine pancreatic insufficiency, including pancreatic (type 3c) diabetes, and can be fatal.
“Acute pancreatitis can lead to chronic pancreatitis, 10,11 signs of exocrine or endocrine pancreatic insufficiency, including pancreatic (type 3c) diabetes, 12 and can be fatal.”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [10] Yang, 2009, The role of free fatty acids, pancreatic lipase and Ca2+ signalling in injury of isolated acinar cells and pancreatitis model in lipoprotein lipase-deficient mice, Acta Physiol (Oxf) source
Not checked in the free run.
- cites [11] Berglund, 2012, Endocrine society. Evaluation and treatment of hypertriglyceridemia: An Endocrine Society clinical practice guideline, J Clin Endocrinol Metab source
Not checked in the free run.
- cites [12] Gaudet, 2013, Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: An open-label trial, Gene Ther source
Not checked in the free run.
Classified as probably not a substantial claim.
Premisecitation§ Dietary guidelines for all patients with FCSThe very-low-fat diet is recommended to reduce TG levels below 1000 mg/dL.
“The very-low-fat diet is recommended to reduce TG levels below 1000 mg/dL.18”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [18] Connor, 1993, N-3 fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients, Ann NY Acad Sci source
Not checked in the free run.
May combine two claims.
Premisecitation§ IntroductionAccumulating TGs may impair pancreatic blood flow and activate inflammatory processes, resulting in acute pancreatitis.
“Accumulating TGs may impair pancreatic blood flow and activate inflammatory processes, resulting in acute pancreatitis. [6][7]7][8]”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [6][7]7][8]
Not checked in the free run.
Classified as probably not a substantial claim.
Premisecitation§ IntroductionPatients with FCS need to avoid drugs known to increase TG levels, including diuretics, systemic steroids, oral estrogens, antihypertensive drugs, retinoids, isotretinoin, bile acid sequestrants, protease inhibitors, immunosuppressants, antidepressants (sertraline), and beta-adrenergic blocking agents.
“In addition to a restricted diet, patients with FCS need to avoid drugs known to increase TG levels, including diuretics, systemic steroids, oral estrogens, antihypertensive drugs, retinoids, isotretinoin, bile acid sequestrants, protease inhibitors, immunosuppressants, antidepressants (sertraline), and beta-adrenergic blocking agents. 1”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [1] Burnett, 1999, Familial lipoprotein lipase deficiency
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Premisecitation§ IntroductionSevere HTG is the cause of 10% of all cases of acute pancreatitis.
“It is estimated that severe HTG is the cause of 10% of all cases of acute pancreatitis.7”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [7] Valdivielso, 2014, Current knowledge of hypertriglyceridemic pancreatitis, Eur J Intern Med source
Not checked in the free run.
May combine two claims.
Premisecitation§ IntroductionPatients with HTG-induced acute pancreatitis may have a more severe course, leading to longer median hospital stays, increased need for intensive care, a higher rate of pancreatic necrosis, more frequent persistent organ failure, and higher rates of mortality.
“acute pancreatitis may have a more severe course, leading to longer median hospital stays, increased need for intensive care, a higher rate of pancreatic necrosis, more frequent persistent organ failure, and higher rates of mortality.9”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [9] Nawaz, 2015, Elevated serum triglycerides are independently associated with persistent organ failure in acute pancreatitis, Am J Gastroenterol source
Not checked in the free run.
May combine two claims.
Premisecitation§ IntroductionAcute pancreatitis was reported by 42% of patients with FCS, making it the most common and potentially severe comorbidity.
“Acute pancreatitis was reported by 42% of patients with FCS, making it the most common and potentially severe comorbidity.13”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [13] Davidson, 2017, The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study, Expert Rev Cardiovasc Ther source
Not checked in the free run.
Classified as probably not a substantial claim.
Premisecitation§ IntroductionWhen LPL is functioning, it helps metabolize TGs into free fatty acids through the LPL-dependent pathway.
“When LPL is functioning, it helps metabolize TGs into free fatty acids through the LPL-dependent pathway.5”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [5] Hegele, 2014, The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis and management, Lancet Diabetes Endocrinol source
Not checked in the free run.
May combine two claims.
Premisecitation§ IntroductionTriglyceride levels in individuals with FCS are often 10-fold to 100-fold or more above normal (<150 mg/dL) and may range from 1500 to 15,000 mg/dL or higher.
“Triglyceride (TG) levels in individuals with FCS are often 10-fold to 100-fold or more above normal (,150 mg/dL) and may range from 1500 to 15,000 mg/ dL or higher.4,5”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [4] Stroes, 2017, Diagnostic algorithm for familial chylomicronemia syndrome, Atheroscler Suppl source
Not checked in the free run.
- cites [5] Hegele, 2014, The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis and management, Lancet Diabetes Endocrinol source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Premisecitation§ IntroductionFamilial chylomicronemia syndrome (FCS) is a rare, autosomal recessive genetic disorder that affects 1 to 2 per million people.
“Familial chylomicronemia syndrome (FCS) is a rare, autosomal recessive genetic disorder that affects 1 to 2 per million people.1,2”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [1] Burnett, 1999, Familial lipoprotein lipase deficiency
Not checked in the free run.
- cites [2] Pouwels, 2008, Severe hypertriglyceridaemia as a result of familial chylomicronaemia: the Cape Town experience, S Afr Med J
Not checked in the free run.
Classified as probably not a substantial claim. May combine two claims.
Premisecitation§ CarbohydratesOverall carbohydrate intake should be limited to <60% daily caloric intake as excess carbohydrates and simple sugar are metabolized into fat, contributing to increased TG levels.
“Overall carbohydrate intake should be limited based on an individual's needs, and to balance macronutrient intake in diet to ,60% daily caloric intake as excess carbohydrates and simple sugar are metabolized into fat, contributing to increased TG levels.33”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [33] National Cholesterol Education Program (NCEP) Expert Panel on Detection, 2002, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), Circulation source
Not checked in the free run.
May combine two claims.
Premisecitation§ Dietary guidelines for all patients with FCSDietary fat retains a pivotal role in provision of adequate calories, preventing EFA deficiency, absorption of fat-soluble vitamins, brain development in infants and children, and increasing satiety.
“Despite the critical need for a very-low-fat intake, dietary fat retains a pivotal role in provision of adequate calories, preventing EFA deficiency, absorption of fat-soluble vitamins, brain development in infants and children, and increasing satiety.24”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [24] Mahan, 2012
Not checked in the free run.
May combine two claims.
Premisecitation§ FatAdequate provision of EFA is necessary to prevent EFA deficiency, characterized by a triene:tetraene ratio of greater than 0.4 or phenotypic signs, including inadequate growth in pediatric patients, dry or dull hair, dry or scaly skin, skin lesions, soft and brittle nails, and impaired wound healing.
“Adequate provision of EFA is necessary to prevent EFA deficiency, characterized by a triene: tetraene ratio of greater than 0.4 or phenotypic signs, including inadequate growth in pediatric patients, dry or dull hair, dry or scaly skin, skin lesions, soft and brittle nails, and impaired wound healing.25”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [25] McCray, 2011, Nutritional management of chyle leaks: an update, Pract Gastroenterol
Not checked in the free run.
May combine two claims.
Premisereasoning§ LimitationsOwing to the low prevalence of FCS, there are no randomized controlled clinical trials or robust data sets.
“Owing to the low prevalence of FCS, there are no randomized controlled clinical trials or robust data sets.”
Quote in the paperSubstantial claimMay combine two claims.
Premisecitation§ Dietary guidelines for all patients with FCSChylomicron concentrations increase as TG levels rise, and both are known causes of acute pancreatitis.
“Chylomicron concentrations increase as TG levels rise, and both are known causes of acute pancreatitis.7”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [7] Valdivielso, 2014, Current knowledge of hypertriglyceridemic pancreatitis, Eur J Intern Med source
Not checked in the free run.
May combine two claims.
Premisecitation§ Fat-soluble vitamin (A, D, E, K) supplementation should beAvoidance of alcohol by patients with FCS is important, as it may cause acute exaggerated TG elevations and exacerbations of acute pancreatitis episodes.
“Avoidance of alcohol by patients with FCS is important, as it may cause acute exaggerated TG elevations and exacerbations of acute pancreatitis episodes.7,36”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [7] Valdivielso, 2014, Current knowledge of hypertriglyceridemic pancreatitis, Eur J Intern Med source
Not checked in the free run.
- cites [36] Yadav, 2009, Alcohol consumption, cigarette smoking, and the risk of recurrent acute and chronic pancreatitis, Arch Intern Med source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Premisecitation§ Fat-soluble vitamin (A, D, E, K) supplementation should bePediatric requirements for fluid are calculated using a child's body surface area.
“Pediatric requirements for fluid are calculated using a child's body surface area.40”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [40] Mosteller, 1987, Simplified calculation of body surface area, N Engl J Med source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Premisecitation§ Fat-soluble vitamin (A, D, E, K) supplementation should beThese may be due to feelings of isolation or due to tiring of following the strict very-low-fat diet.
“These may be due to feelings of isolation or due to tiring of following the strict verylow-fat diet.42,43”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [42] Wells, 1998, Alterations in mood after changing to a low-fat diet, Br J Nutr source
Not checked in the free run.
- cites [43] Brinkworth, 2009, Long-term effects of a very low-carbohydrate diet and a low-fat diet on mood and cognitive function, Arch Intern Med source
Not checked in the free run.
May combine two claims.
Premisecitation§ FatMCT oil is used to increase overall caloric intake and adjust the macronutrient distribution of the diet, helping to prevent excessive percentage of overall caloric intake from carbohydrate sources.
“MCT oil is used to increase overall caloric intake and adjust the macronutrient distribution of the diet, helping to prevent excessive percentage of overall caloric intake from carbohydrate sources.28,29”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [28] Ahmad, 2014, Familial chylomicronemia syndrome and response to medium-chain triglyceride therapy in an infant with novel mutations in GPIHBP1, J Clin Lipidol source
Not checked in the free run.
- cites [29] Bach, 1982, Medium-chain triglycerides: an update, Am J Clin Nutr source
Not checked in the free run.
May combine two claims.
Premisecitation§ Special populations Pregnancy and FCSThe high TG levels allow the mother to spare glucose for the fetus and allow placental steroidogenesis.
“The high TG levels allow the mother to spare glucose for the fetus and allow placental steroidogenesis.47”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [47] Bolla, 2012, Chylomicronemia syndrome in pregnancy: a case report of an acute necrotizing pancreatitis, Geburtshilfe Frauenheilkd source
Not checked in the free run.
Classified as probably not a substantial claim.
Study design and conductreasoning§ LimitationsThese guidelines are based on limited observations and clinical experience.
“Thus, these guidelines are based on limited observations and clinical experience.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Premisecitation§ Chronic pancreatitisEPI occurs when 90% of the pancreatic enzyme output is diminished.
“EPI occurs when 90% of the pancreatic enzyme output is diminished, 54 and pancreatic enzyme replacement therapies may be necessary in such cases.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [54] Ferrone, 2007, Pancreatic enzyme pharmacotherapy, Pharmacotherapy source
Not checked in the free run.
Classified as probably not a substantial claim.
Premisecitation§ FatTo prevent EFA deficiency, a minimum intake of 2% to 4% daily caloric intake from LA and ALA is recommended.
“To prevent EFA deficiency, a minimum intake of 2% to 4% daily caloric intake from LA and ALA is recommended.26”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [26] Elmadfa, 2009, Fats and fatty acid requirements for adults, Ann Nutr Metab source
Not checked in the free run.
May combine two claims.
Premisecitation§ Fat-soluble vitamin (A, D, E, K) supplementation should beMetabolic syndrome and insulin resistance may lead to further elevated TG levels, and should be prevented.
“Metabolic syndrome and insulin resistance may lead to further elevated TG levels, and should be prevented.35”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [35] Miller, 2011, Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association, Circulation source
Not checked in the free run.
Classified as probably not a substantial claim.
Study design and conductreasoning§ LimitationsThese best practice guidelines are based on a review of the literature and expert opinion of RDNs with experience providing medical nutrition therapy for patients with FCS.
“These best practice guidelines (summarized in Table 5) are based on a review of the literature and expert opinion of RDNs with experience providing medical nutrition therapy for patients with FCS.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing), S4 (based).
Interpretationnone given§ ConclusionsMany families, caregivers, and patients benefit from communicating and connecting with other people with FCS.
“Many families, caregivers, and patients benefit from communicating and connecting with other people with FCS, which can occur through the FCS Foundation (www. livingwithfcs.org;www.facebook.com/livingwithfcs).”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S2 (checkable), S4 (based).
Interpretationreasoning§ ConclusionsThe support of the health care team or the FCS Foundation may enable patients with FCS to better adhere to and manage the very-low-fat diet.
“The support of the health care team or the FCS Foundation may enable patients with FCS to better adhere to and manage the very-low-fat diet.”
Quote in the paperNot a substantial claim- Rests on an assumption: The very-low-fat diet is essential for FCS.
Probably not a substantial claim: may not pass S2 (checkable), S4 (based).
Interpretationreasoning§ ConclusionsPeople with FCS who feel empowered to control and individualize their diet to their own tastes and needs may increase their adherence to the very-low-fat diet.
“It is possible that people with FCS who feel empowered to control and individualize their diet to their own tastes and needs may increase their adherence to the very-low-fat diet.”
Quote in the paperNot a substantial claim- Rests on an assumption: The very-low-fat diet is essential for FCS.
May combine two claims.
Premisecitation§ ConclusionsPatients with FCS are at risk for feelings of isolation, tension, anxiety, and development of eating disorders.
“It is important to consider and discuss the psychosocial implications of dietary management with FCS patients, including risk for feelings of isolation, tension, anxiety, and development of eating disorders.[41][42][43]”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [41][42][43]
Not checked in the free run.
May combine two claims.
Premisecitation§ ConclusionsPatients with FCS report cognitive symptoms such as impaired memory, difficulty concentrating, fatigue, and weakness.
“Twenty-two percent of FCS patients reported depressive episodes, and other cognitive symptoms such as impaired memory, difficulty concentrating, fatigue, and weakness.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [13] Davidson, 2017, The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study, Expert Rev Cardiovasc Ther source
Not checked in the free run.
Probably not a substantial claim: may not pass S2 (checkable), S4 (based).
Interpretationnone given§ ConclusionsPatients with FCS benefit from working with a multidisciplinary team.
“Patients with FCS benefit from working with a multidisciplinary team.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim.
Premisecitation§ ConclusionsThis approach empowers patients with FCS to discover and use their own innate ability to gain mastery over their disease.
“This approach empowers patients with FCS to discover and use their own innate ability to gain mastery over their disease.62”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [62] Anderson, 2010, Patient empowerment: myths and misconceptions, Patient Educ Couns source
Not checked in the free run.
The paper relies on this without support.
FCS is characterized by severe fasting hypertriglyceridemia due to a deficiency in either the enzyme lipoprotein lipase (LPL) or other proteins necessary for proper LPL function.
“FCS is characterized by severe fasting hypertriglyceridemia (HTG) due to a deficiency in either the enzyme lipoprotein lipase (LPL) or other proteins necessary for proper LPL function.”
The paper relies on this without support.
In FCS, HTG results from the inability to metabolize TGs and other fats.
“In FCS, HTG results from the inability to metabolize TGs and other fats.”
The paper relies on this without support.
Fats are absorbed through the small intestine, where chylomicrons are formed.
“Fats are absorbed through the small intestine, where chylomicrons are formed.”
The paper relies on this without support.
Although TGs are also metabolized via the LPL-independent pathway, this pathway cannot compensate for the loss of LPL function.
“Although TGs are also metabolized via the LPL-independent pathway, this pathway cannot compensate for the loss of LPL function.”
The paper relies on this without support.
In FCS, chylomicrons, chylomicron remnants, and TG-rich lipoproteins cannot be metabolized and accumulate in the plasma.
“In FCS, chylomicrons, chylomicron remnants, and TGrich lipoproteins cannot be metabolized and accumulate in the plasma.”
The paper relies on this without support.
Acute pancreatitis is one of the severe, debilitating symptoms of FCS.
“Acute pancreatitis is one of the severe, debilitating symptoms of FCS.”
The paper relies on this without support.
Current medical nutrition therapy for FCS is a very-low-fat diet consisting of total fat intake <10% to 15% daily calories (ie, <15-20 g of fat per day) with limited simple, refined carbohydrates and avoidance of alcohol.
“Because patients with FCS cannot metabolize TGs and fats, current medical nutrition therapy is a very-low-fat diet consisting of total fat intake ,10% to 15% daily calories (ie, ,15-20 g of fat per day) with limited simple, refined carbohydrates and avoidance of alcohol.”
The paper relies on this without support.
At the present time, there are no Food and Drug Administration-approved treatments for FCS.
“At the present time, there are no Food and Drug Administration-approved treatments for FCS.”
The paper relies on this without support.
Short-term ingestion of dietary fat, and even limited alcohol consumption, can result in highly exaggerated TG elevations that place patients at high risk for acute pancreatitis, despite otherwise good adherence with the diet.
“Short-term ingestion of dietary fat, and even limited alcohol consumption, can result in highly exaggerated TG elevations that place patients at high risk for acute pancreatitis, despite otherwise good adherence with the diet.”
The paper relies on this without support.
FCS is diagnosed as severe, refractory HTG in people with a history of acute pancreatitis or recurrent abdominal pain and the absence of other causes (alcoholism, gallstones, uncontrolled diabetes, medications, or medical conditions known to cause HTG).
“FCS is diagnosed as severe, refractory HTG in people with a history of acute pancreatitis or recurrent abdominal pain and the absence of other causes (alcoholism, gallstones, uncontrolled diabetes, medications, or medical conditions known to cause HTG).”
The paper relies on this without support.
The most distinctive clinical feature of FCS is fasting hyperchylomicronemia, which results in lipemic, milky-appearing plasma samples.
“The most distinctive clinical feature of FCS is fasting hyperchylomicronemia, which results in lipemic, milkyappearing plasma samples.”
The paper relies on this without support.
There are no randomized controlled trials or meta-analyses, in part due to rareness of the condition.
“There are also no randomized controlled trials or meta-analyses, in part due to rareness of the condition.”
The paper relies on this without support.
HTG increases the severity of acute pancreatitis.
“HTG increases the severity of acute pancreatitis.”
The paper relies on this without support.
A nutrition facts label may be rounded and not indicate the absolute amount of fat in foods.
“It is important to note that a nutrition facts label may be rounded and not indicate the absolute amount of fat in foods.”
The paper relies on this without support.
An individual's recommended fat intake varies based on age and caloric needs, and may need to be modified during pregnancy and for special populations (eg, diabetes).
“An individual's recommended fat intake varies based on age and caloric needs, and may need to be modified during pregnancy and for special populations (eg, diabetes) as is discussed later in this article.”
The paper relies on this without support.
The body can produce all fatty acids except the EFAs, LA, an omega-6 fatty acid, and ALA, an omega-3 fatty acid.
“The body can produce all fatty acids except the EFAs, LA, an omega-6 fatty acid, and ALA, an omega-3 fatty acid.”
The paper relies on this without support.
As EFAs, LA and ALA must be ingested by individuals of all ages.
“As EFAs, LA, and ALA must be ingested by individuals of all ages.”
The paper relies on this without support.
Data is limited in humans regarding the minimum requirements of LA and ALA.
“Data is limited in humans regarding the minimum requirements of LA and ALA.”
The paper relies on this without support.
Over-the-counter omega-3 or fish oil supplements are not recommended due to lack of regulation by the Food and Drug Administration and lower concentration of eicosapentaenoic acid and docosahexaenoic acid in over-the-counter supplements vs prescription.
“It is important to note that over-the-counter omega-3 or fish oil supplements are not recommended due to lack of regulation by the Food and Drug Administration and lower concentration of eicosapentaenoic acid and docosahexaenoic acid in over-thecounter supplements vs prescription.”
The paper relies on this without support.
MCT oil is a medical food available via prescription and should not be confused with coconut oil, which provides additional long-chain triglyceride (LCT) as well as lauric acid (C12).
“MCT oil is a medical food available via prescription and should not be confused with coconut oil, which provides additional long-chain triglyceride (LCT) as well as lauric acid (C12).”
The paper relies on this without support.
Much of lauric acid is absorbed via the chylomicron-dependent pathway.
“It is important to note that much of lauric acid is absorbed via the chylomicron-dependent pathway.”
The paper relies on this without support.
Coconut oil has both medium-chain and long-chain fatty acids, whereas medical grade MCT oil contains only medium-chain fatty acids (ie, C8 and C10).
“Coconut oil has both medium-chain and long-chain fatty acids, whereas medical grade MCT oil contains only medium-chain fatty acids (ie, C8 and C10).”
The paper relies on this without support.
MCT oils sold over the counter may also contain lauric acid and are not recommended for consumption by patients with FCS.
“MCT oils sold over the counter may also contain lauric acid and are not recommended for consumption by patients with FCS.”
The paper relies on this without support.
Low-fat or fat-free, protein-rich foods allow individuals to meet their specific protein requirements while maintaining overall recommended fat restriction.
“Low-fat or fat-free, protein-rich foods allow individuals to meet their specific protein requirements while maintaining overall recommended fat restriction.”
The paper relies on this without support.
Protein-rich foods high in unsaturated fat, such as salmon, nuts, and seeds, would not be appropriate in the recommended diet as long-chain saturated fat, trans fat, and unsaturated fat are all metabolized using the LPL-dependent pathway.
“It is important to note that protein-rich foods high in unsaturated fat, such as salmon, nuts, and seeds, would not be appropriate in the recommended diet as long-chain saturated fat, transfat, and unsaturated fat are all metabolized using the LPL-dependent pathway.”
The paper relies on this without support.
Alcohol interferes with normal TG metabolism and promotes the accumulation of fat in the liver, which subsequently leads to increase in blood chylomicron levels and HTG.
“Alcohol interferes with normal TG metabolism and promotes the accumulation of fat in the liver, which subsequently leads to increase in blood chylomicron levels and HTG.”
The paper relies on this without support.
Individuals with FCS must maintain adequate fluid intake to assist in maintaining hydration and proper pancreatic function.
“Individuals with FCS must maintain adequate fluid intake to assist in maintaining hydration and proper pancreatic function.”
The paper relies on this without support.
Water intake is necessary for digestion.
“Water intake is necessary for digestion.”
The paper relies on this without support.
Patients with FCS have a higher risk of complications, especially acute pancreatitis during pregnancy.
“Patients with FCS have a higher risk of complications, especially acute pancreatitis during pregnancy.”
The paper relies on this without support.
This patient population is at risk for malabsorption and impaired insulin and glucagon secretion due to loss of exocrine and endocrine function.
“This patient population is at risk for malabsorption and impaired insulin and glucagon secretion due to loss of exocrine and endocrine function.”
The paper relies on this without support.
Patients with pancreatogenic diabetes have impaired metabolism of fats, which may result in deficiencies in fat-soluble vitamins, particularly vitamin D.
“Patients with pancreatogenic diabetes have impaired metabolism of fats, which may result in deficiencies in fat-soluble vitamins, particularly vitamin D.”
The paper relies on this without support.
Glycemic control is an important part of TG reduction, as well as prevention of diabetes-related complications.
“Glycemic control is an important part of TG reduction, as well as prevention of diabetes-related complications.”
The paper relies on this without support.
Recurrent acute pancreatitis from persistently elevated TGs increases the risk of chronic pancreatitis due to irreversible damage to the pancreas.
“Recurrent acute pancreatitis from persistently elevated TGs increases the risk of chronic pancreatitis due to irreversible damage to the pancreas.”
The paper relies on this without support.
Patients exhibiting gastrointestinal symptoms of diarrhea, gas, bloating, and unexplained weight loss may be at risk for exocrine pancreatic insufficiency.
“Patients exhibiting gastrointestinal symptoms of diarrhea, gas, bloating, and unexplained weight loss may be at risk for exocrine pancreatic insufficiency (EPI).”
The paper relies on this without support.
At this time, the percentage of patients with FCS who develop EPI and chronic pancreatitis is unknown.
“At this time, the percentage of patients with FCS who develop EPI and chronic pancreatitis is unknown.”
The paper relies on this without support.
Diet and lifestyle are the mainstays of FCS management to decrease TG levels and reduce the likelihood of pancreatitis.
“Diet and lifestyle are the mainstays of FCS management to decrease TG levels and reduce the likelihood of pancreatitis.”
The paper relies on this without support.
Even with strict diet adherence, some patients still experience acute pancreatitis, elevated TGs, and other complications, and struggle with daily discomfort.
“Even with strict diet adherence, some patients still experience acute pancreatitis, elevated TGs, and other complications, and struggle with daily discomfort.”
The paper relies on this without support.
TGs below 2000 mg/dL may prevent pain in some patients with FCS.
“TGs below 2000 mg/dL may prevent pain in some patients, and maintenance of TGs below 1000 mg/dL is the target for patients with FCS.”
The paper relies on this without support.
The very-low-fat diet is essential for FCS.
“These guidelines are intended to help RDNs, clinicians, patients with FCS, their families, and caregivers manage the very-low-fat dietary pattern essential for FCS.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Severely fat-restricted diets may be useful to reduce chylomicronemia and hypertriglyceridemia but are difficult to maintain in the long term.
“Severely fat-restricted diets may be useful to reduce chylomicronemia and hypertriglyceridemia but are difficult to maintain in the long term. 16”
From Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (2024) · cites this paper as [16]
Cites
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198 · see citing works
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928 · see citing works
Patient Self-management of Chronic Disease in Primary Care
Bodenheimer, T. (2002) · JAMA · doi:10.1001/jama.288.19.2469 · Cited by 3,598 · see citing works
Simplified calculation of body surface area
(1987) · New England Journal of Medicine · doi:10.1056/nejm198710223171717 · Cited by 3,238 · see citing works
American College of Gastroenterology guideline: management of acute pancreatitis
Tenner, S., Baillie, J., DeWitt, J., & Vege, S. S. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.218 · Cited by 2,327 · cited 1× · see citing works
“During attacks of acute pancreatitis, early aggressive IV hydration with 250 to 500 mL/h may prevent intravascular volume depletion and pancreatic necrosis.(50,51) Ideally, initiating IV hydration within the first 12 hours of acute pancreatitis onset may prevent further complications.”
BackgroundPractice guidelines in acute pancreatitis
Banks, P. A., Freeman, M. L., & the Practice Parameters Committee of the American College of Gastroenterology (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00856.x · Cited by 2,050 · see citing works
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871 · see citing works
Medium-chain triglycerides: an update
Bach, A., & Babayan, V. (1982) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/36.5.950 · Cited by 1,151 · see citing works
Motivational interviewing in health care: helping patients change behavior
(2008) · Choice Reviews Online · doi:10.5860/choice.45-6211 · Cited by 907 · see citing works
Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887 · see citing works
Patient empowerment: myths and misconceptions
Anderson, R. M., & Funnell, M. M. (2010) · Patient Education and Counseling · doi:10.1016/j.pec.2009.07.025 · Cited by 846 · see citing works
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784 · see citing works
Hegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70191-8 · Cited by 635 · see citing works
Hypertriglyceridemia: its etiology, effects and treatment
Yuan, G., Al-Shali, K. Z., & Hegele, R. A. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.060963 · Cited by 624 · see citing works
Alcohol Consumption, Cigarette Smoking, and the Risk of Recurrent Acute and Chronic Pancreatitis
Yadav, D. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.125 · Cited by 466 · see citing works
Current knowledge of hypertriglyceridemic pancreatitis
Valdivielso, P., Ramírez-Bueno, A., & Ewald, N. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.08.008 · Cited by 439 · see citing works
Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404 · see citing works
Chylomicronaemia–current diagnosis and future therapies
Brahm, A. J., & Hegele, R. A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.26 · Cited by 356 · see citing works
Nawaz, H., Koutroumpakis, E., Easler, J., Slivka, A., Whitcomb, D. C., Singh, V. P., Yadav, D., & Papachristou, G. I. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.261 · Cited by 296 · see citing works
Brunzell, J. D. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp070061 · Cited by 268 · see citing works
Rickels, M. R., Bellin, M., Toledo, F. G. S., Robertson, R. P., Andersen, D. K., Chari, S. T., Brand, R., Frulloni, L., Anderson, M. A., & Whitcomb, D. C. (2013) · Pancreatology · doi:10.1016/j.pan.2013.05.002 · Cited by 249 · see citing works
Compliance and Adherence are Dysfunctional Concepts in Diabetes Care
Anderson, R. M., & Funnell, M. M. (2000) · The Science of Diabetes Self-Management and Care · doi:10.1177/014572170002600405 · Cited by 233 · see citing works
(2001) · Medical Entomology and Zoology · Cited by 227 · see citing works
Maio, A., & Dowd, F. J. (2008) · xPharm: The Comprehensive Pharmacology Reference · doi:10.1016/b978-008055232-3.60628-2 · Cited by 207 · see citing works
Long-term effects of a very low-carbohydrate diet and a low-fat diet on mood and cognitive function
Brinkworth, G. D. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.329 · Cited by 205 · see citing works
Fluid resuscitation in acute pancreatitis
Gardner, T. B., Vege, S. S., Pearson, R. K., & Chari, S. T. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.05.005 · Cited by 201 · see citing works
Lessons learned from the clinical development and market authorization of Glybera
Bryant, L. M., Christopher, D. M., Giles, A. R., Hinderer, C., Rodriguez, J. L., Smith, J. B., Traxler, E. A., Tycko, J., Wojno, A. P., & Wilson, J. M. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.087 · Cited by 189 · see citing works
Severe hypertriglyceridemia in pregnancy
Goldberg, A. S., & Hegele, R. A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1250 · Cited by 187 · see citing works
Hypertriglyceridemia and acute pancreatitis
Murphy, M. J., Sheng, X., MacDonald, T. M., & Wei, L. (2013) · JAMA Internal Medicine · doi:10.1001/2013.jamainternmed.477 · Cited by 172 · see citing works
Hypertriglyceridemia-induced pancreatitis: A case-based review
Gan, S. I. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i44.7197 · Cited by 168 · see citing works
THE FAMILIAL CHYLOMICRONEMIA SYNDROME
Santamarina-Fojo, S. (1998) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70025-6 · Cited by 162 · see citing works
Fats and fatty acid requirements for adults
Elmadfa, I., & Kornsteiner, M. (2009) · Annals of Nutrition and Metabolism · doi:10.1159/000228996 · Cited by 161 · see citing works
Diagnostic algorithm for familial chylomicronemia syndrome
Stroes, E., Moulin, P., Parhofer, K. G., Rebours, V., Löhr, J.-M., & Averna, M. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2016.10.002 · Cited by 130 · see citing works
CONNOR, W. E., DeFRANCESCO, C. A., & CONNOR, S. L. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb35689.x · Cited by 119 · see citing works
Environmental health attitudes and behaviors: findings from a large pregnancy cohort study
Barrett, E. S., Sathyanarayana, S., Janssen, S. J., Redmon, J. B., Nguyen, R. H. N., Kobrosly, R. W., & Swan, S. H. (2014) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2014.02.029 · Cited by 105 · see citing works
WARTH, M. R., ARKY, R. A., & KNOPP, R. H. (1975) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-41-4-649 · Cited by 100 · see citing works
Yang, F., Wang, Y., Sternfeld, L., Rodriguez, J. A., Ross, C., Hayden, M. R., Carriere, F., Liu, G., & Schulz, I. (2009) · Acta Physiologica · doi:10.1111/j.1748-1716.2008.01933.x · Cited by 93 · see citing works
Pancreatic enzyme pharmacotherapy
Ferrone, M., Raimondo, M., & Scolapio, J. S. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.6.910 · Cited by 88 · see citing works
Alterations in mood after changing to a low-fat diet
Wells, A. S., Read, N. W., Laugharne, J. D. E., & Ahluwalia, N. S. (1998) · British Journal Of Nutrition · doi:10.1079/bjn19980005 · Cited by 67 · see citing works
The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study
Davidson, M., Stevenson, M., Hsieh, A., Ahmad, Z., Crowson, C., & Witztum, J. L. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1311786 · Cited by 54 · see citing works
Ahmad, Z., & Wilson, D. P. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.08.010 · Cited by 43 · see citing works
Gaudet, D., Blom, D., Bruckert, E., Stroes, E., Kastelein, J., John, K., Malloy, M., Moulin, P., Retterstøļl, K., Hughes, S., et al. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.03.048 · Cited by 30 · see citing works
Building a better understanding of the burden of disease in familial chylomicronemia syndrome
Ahmad, Z., Halter, R., & Stevenson, M. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1251839 · Cited by 28 · see citing works
Chamma, C. M. D. O., Bargut, T. C. L., Mandarim-de-Lacerda, C. A., & Aguila, M. B. (2017) · Food & Function · doi:10.1039/c6fo01663d · Cited by 27 · see citing works
Pschierer, V., Richter, W. O., & Schwandt, P. (1995) · The Journal of Nutrition · doi:10.1093/jn/125.6.1490 · Cited by 26 · see citing works
Editorial commentary: Dietary management of familial chylomicronemia syndrome
Williams, L., & Wilson, D. P. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.12.023 · Cited by 24 · see citing works
Self-citationSevere hypertriglyceridaemia as a result of familial chylomicronaemia: the Cape Town experience.
Pouwels, E. D., Blom, D. J., Firth, J. C., Henderson, H., & Marais, A. D. (2008) · PubMed · Cited by 23 · see citing works
Steinhagen‐Thiessen, E., Stroes, E. S. G., Soran, H., Johnson, C., Moulin, P., Iotti, G., Zibellini, M., Ossenkoppele, B., Dippel, M., & Averna, M. R. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.023 · Cited by 23 · see citing works
JCL Roundtable: Hypertriglyceridemia due to defects in lipoprotein lipase function
Brown, W. V., Goldberg, I. J., & Young, S. G. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.03.009 · Cited by 18 · see citing works
Gavish, D. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.147.4.705 · Cited by 15 · see citing works
Hauenschild, A., Ewald, N., Schnell-Kretschmer, H., Porsch-Oezcueruemez, M., Kloer, H.-U., & Hardt, P. D. (2008) · Annals of Nutrition and Metabolism · doi:10.1159/000138126 · Cited by 15 · see citing works
Adherence to a low-fat diet in men with prostate cancer
Link, L. B., Thompson, S. M., Bosland, M. C., & Lumey, L. H. (2004) · Urology · doi:10.1016/j.urology.2004.06.040 · Cited by 15 · see citing works
Severe Hypertriglyceridaemia as a result of Familial Chylomicronaemia
Pouwels, E. D., Blom, D. J., Firth, J. C., Henderson, H., & Marais, A. D. (2008) · South African Medical Journal · doi:10.7196/samj.424 · Cited by 14 · see citing works
Helk, O., Schreiber, R., & Widhalm, K. (2016) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2016.70 · Cited by 14 · see citing works
Gavish, D. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.1987.00370040087015 · Cited by 14 · see citing works
Densupsoontorn, N., Jirapinyo, P., Tirapongporn, H., Wongarn, R., Chotipanang, K., Phuangphan, P., & Chongviriyaphan, N. (2014) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.14-35 · Cited by 12 · see citing works
Whitfield-Brown, L. M., Hamer, O., Ellahi, B., Burden, S. T., & Durrington, P. N. (2009) · Journal of Human Nutrition and Dietetics · doi:10.1111/j.1365-277x.2009.00945.x · Cited by 9 · see citing works
Chylomicronemia syndrome in pregnancy: a case report of an acute necrotizing pancreatitis
Bolla, D., Schyrba, V., Drack, G., Schöning, A., Stage, A., & Hornung, R. (2012) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0032-1315295 · Cited by 3 · see citing works
Latex Allergy: A Primer for Diabetes Educators
McAndrew, M., & Gritter, M. (1999) · The Science of Diabetes Self-Management and Care · doi:10.1177/014572179902500412 · Cited by 2 · see citing works
Flagged first, then by citations
2 of the 62 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- McCray, 2011, Nutritional management of chyle leaks: an update, Pract Gastroenterol, 35, 12
- Tenner, 2013, American College of Gastroenterology Guideline: Management of Acute Pancreatitis, Am J Gastroenterol, 22, 433
Cited by
Sorted by citations
Kirkpatrick, C. F., Bolick, J. P., Kris-Etherton, P. M., Sikand, G., Aspry, K. E., Soffer, D. E., Willard, K.-E., & Maki, K. C. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.08.003 · Cited by 390 · see citing works
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome
Stroes, E. S. G., Alexander, V. J., Karwatowska-Prokopczuk, E., Hegele, R. A., Arca, M., Ballantyne, C. M., Soran, H., Prohaska, T. A., Xia, S., Ginsberg, H. N., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2400201 · Cited by 271 · see citing works
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.11.016 · Cited by 304 · see citing works
Management of hypertriglyceridemia
Simha, V. (2020) · BMJ · doi:10.1136/bmj.m3109 · Cited by 227 · see citing works
Writing Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001423 · Cited by 122 · see citing works
Role of Medium-Chain Fatty Acids in Healthy Metabolism: A Clinical Perspective
Huang, L., Gao, L., & Chen, C. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.03.002 · Cited by 122 · see citing works
Kirkpatrick, C. F., Sikand, G., Petersen, K. S., Anderson, C. A. M., Aspry, K. E., Bolick, J. P., Kris‐Etherton, P. M., & Maki, K. C. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.05.099 · Cited by 128 · see citing works
Chen, G., Harwood, J. L., Lemieux, M. J., Stone, S. J., & Weselake, R. J. (2022) · Progress in Lipid Research · doi:10.1016/j.plipres.2022.101181 · Cited by 118 · see citing works
Hernández, P., Passi, N., Modarressi, T., Kulkarni, V., Soni, M., Burke, F., Bajaj, A., & Soffer, D. E. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00962-z · Cited by 74 · see citing works
Guidance for the diagnosis and treatment of hypolipidemia disorders
Bredefeld, C., Hussain, M. M., Averna, M. R., Black, D. D., Brin, M. F., Burnett, J. R., Charrière, S., Cuerq, C., Davidson, N. O., Deckelbaum, R. J., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.08.009 · Cited by 72 · see citing works
Self-citationO'Dea, L. S. L., MacDougall, J., Alexander, V. J., DIGENIO, A. G., Hubbard, B., Arca, M., Moriarty, P. M., Kastelein, J. J. P., Bruckert, É., Soran, H., et al. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00214 · Cited by 62 · see citing works
Familial chylomicronemia syndrome: An expert clinical review from the National Lipid Association
Javed, F., Hegele, R. A., Garg, A., Patni, N., Gaudet, D., Williams, L., Khan, M., Li, Q., & Ahmad, Z. (2025) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2025.03.013 · Cited by 60 · see citing works
Self-citationAlexopoulos, A., Qamar, A., Hutchins, K., Crowley, M. J., Batch, B. C., & Guyton, J. R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1136-3 · Cited by 60 · see citing works
Posicionamento sobre o Consumo de Gorduras e Saúde Cardiovascular – 2021
Izar, M. C. D. O., Lottenberg, A. M., Giraldez, V. Z. R., Santos, R. D., Machado, R. M., Bertolami, A., Assad, M. H. V., Saraiva, J. F. K., Faludi, A. Á., Moreira, A. S. B., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20201340 · Cited by 65 · see citing works
New Therapies for Primary Hyperlipidemia
Aguilar-Salinas, C. A., Gómez-Díaz, R. A., & Corral, P. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab876 · Cited by 60 · see citing works
Agarwala, A., Dixon, D. L., Gianos, E., Kirkpatrick, C. F., Michos, E. D., Satish, P., Birtcher, K. K., Braun, L. T., Pillai, P., Watson, K., et al. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.05.005 · Cited by 57 · see citing works
Hypertriglyceridemia: new approaches in management and treatment
Wolska, A. T., Yang, Z., & Remaley, A. T. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000710 · Cited by 50 · see citing works
Extreme hypertriglyceridemia: genetic diversity, pancreatitis, pregnancy, and prevalence
Chyzhyk, V., Kozmic, S., Brown, A. S., Hudgins, L. C., Starc, T. J., Davila, A. D., Blevins, T. C., Diffenderfer, M. R., He, L., Geller, A. S., et al. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.09.007 · Cited by 44 · see citing works
Current Diagnosis and Management of Primary Chylomicronemia
Okazaki, H., Gotoda, T., Ogura, M., Ishibashi, S., Inagaki, K., Daida, H., Hayashi, T., Hori, M., Masuda, D., Matsuki, K., et al. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17054 · Cited by 44 · see citing works
Bashir, B., Ho, J. H., DOWNIE, P. F., Hamilton, P., Ferns, G. A., Datta, D. B. N., Cegla, J., Wierzbicki, A. S., Dawson, C., Jenkinson, F., et al. (2023) · Metabolites · doi:10.3390/metabo13050621 · Cited by 45 · see citing works
Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment
Gallo, A., Béliard, S., D’Erasmo, L., & Bruckert, É. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00885-1 · Cited by 44 · see citing works
Screening and Management of Dyslipidemia in Children and Adolescents
Schefelker, J., & Peterson, A. L. H. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11216479 · Cited by 43 · see citing works
Hegele, R. A., Ahmad, Z., Ashraf, A. P., Baldassarra, A., Brown, A. S., Chait, A., Freedman, S. D., Kohn, B., Miller, M. J., Patni, N., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.09.008 · Cited by 40 · see citing works
The biochemical and genetic diagnosis of lipid disorders
Schaefer, E. J., Geller, A. S., & Endress, G. A. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000590 · Cited by 37 · see citing works
Safety and efficacy of therapies for chylomicronemia
Shamsudeen, I., & Hegele, R. A. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2094768 · Cited by 37 · see citing works
Zhan, W., Peng, H., Xie, S., Deng, Y., Zhu, T., Cui, Y., Cao, H., Tang, Z., Jin, M., & Zhou, Q. (2024) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2024.109739 · Cited by 34 · see citing works
Williams, L. H., Baker-Smith, C. M., Bolick, J. P., Carter, J., Kirkpatrick, C. F., Ley, S. L., Peterson, A. L. H., SHAH, A. S., Sikand, G., Ware, A. L., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.07.011 · Cited by 27 · see citing works
Self-citationEruptive Xanthomas: Importance of Recognition to Reduce Delay of Effective Triglyceride Reduction
Marogi, E. P., Ohiomoba, R., & Stone, N. J. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.09.026 · Cited by 25 · see citing works
Garg, A., Garg, V., Hegele, R. A., & Lewis, G. F. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30156-1 · Cited by 24 · see citing works
D’Erasmo, L., Gallo, A., Costanzo, A. D., Bruckert, É., & Arca, M. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1787380 · Cited by 24 · see citing works
Efficacy and safety of lomitapide in familial chylomicronaemia syndrome
Cefalu, A. B., D’Erasmo, L., Iannuzzo, G., Noto, D., Giammanco, A., Montali, A., Zambon, A., Forte, F., Suppressa, P., Giannini, S., et al. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.08.017 · Cited by 24 · see citing works
Syed‐Abdul, M. M., Tian, L., Hegele, R. A., & Lewis, G. F. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00028-2 · Cited by 21 · see citing works
Characteristics, Physiopathology and Management of Dyslipidemias in Pregnancy: A Narrative Review
Formisano, E., Proietti, E., Perrone, G., Demarco, V., Galoppi, P., Stefanutti, C., & Pisciotta, L. (2024) · Nutrients · doi:10.3390/nu16172927 · Cited by 22 · see citing works
Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA
Brinton, E. A., Eckel, R. H., Gaudet, D., Ballantyne, C. M., Baker, B. F., Ginsberg, H. N., & Witztum, J. L. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119114 · Cited by 20 · see citing works
Patel, S. B., Belalcazar, L. M., Afreen, S., Balderas, R., Hegele, R. A., Karpe, F., Ponte-Negretti, C. I., & Rajpal, A. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.014 · Cited by 19 · see citing works
Update on the diagnosis, treatment and management of rare genetic lipid disorders
Ng, D., Burnett, J. R., Bell, D. A., Hegele, R. A., & Hooper, A. J. (2018) · Pathology · doi:10.1016/j.pathol.2018.11.005 · Cited by 17 · see citing works
Saadatagah, S., Larouche, M., Naderian, M., Nambi, V., Brisson, D., Kullo, I. J., Duell, P. B., Michos, E. D., Shapiro, M. D., Watts, G. F., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.03.012 · Cited by 17 · see citing works
Saadatagah, S., Larouche, M., Naderian, M., Nambi, V., Brisson, D., Kullo, I. J., Duell, P. B., Michos, E. D., Shapiro, M. D., Watts, G. F., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100978 · Cited by 16 · see citing works
Salvatore, V., Gilstrap, A., Williams, K. R., Thorat, S., Stevenson, M. T., Gwosdow, A. R., Hsieh, A., Hubbard, B., & Davidson, D. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1505495 · Cited by 15 · see citing works
Kuthiroly, S., Yesodharan, D., Radhakrishnan, N., Ganapathy, A., Mannan, A. U., Hoffmann, M. M., & Nampoothiri, S. (2020) · The Indian Journal of Pediatrics · doi:10.1007/s12098-020-03305-z · Cited by 15 · see citing works
Recent Apolipoprotein CIII trials
Tramontano, D., Bini, S., D’Erasmo, L., & Arca, M. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000849 · Cited by 14 · see citing works
Pancreatic and cardiometabolic complications of severe hypertriglyceridaemia
Bashir, B., Ferdousi, M., Durrington, P. N., & Soran, H. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000939 · Cited by 14 · see citing works
Capra, M. E., Biasucci, G., Banderali, G., & Pederiva, C. (2023) · Nutrients · doi:10.3390/nu15051088 · Cited by 13 · see citing works
Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia
Larouche, M., Khoury, É., Brisson, D., & Gaudet, D. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01179-y · Cited by 14 · see citing works
Novel Therapeutics for Familial Chylomicronemia Syndrome
Izar, M. C. D. O., & Fonseca, F. A. H. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01295-x · Cited by 13 · see citing works
Thajer, A., Skacel, G., de Gier, C., & Greber‐Platzer, S. (2021) · Children · doi:10.3390/children8111078 · Cited by 12 · see citing works
Aljouda, L., Nagy, L. L., & Schulze, A. (2023) · Nutrients · doi:10.3390/nu15163535 · Cited by 14 · see citing works
Fox, R. S., Peipert, J. D., Vera‐Llonch, M., Phillips, G. A., & Cella, D. F. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1748011 · Cited by 12 · see citing works
Familial chylomicronemia syndrome: a case report
Susheela, A., Vadakapet, P., Pillai, L. N., & Thampi, S. (2021) · Journal of Medical Case Reports · doi:10.1186/s13256-020-02609-0 · Cited by 11 · see citing works
Olezarsen for the Treatment of Familial Chylomicronemia Syndrome
Phillips, B., Abbott, C., Breit, S., & Onge, E. S. (2025) · Annals of Pharmacotherapy · doi:10.1177/10600280251332500 · Cited by 9 · see citing works
The Prevalence of Probable Familial Chylomicronemia Syndrome in a Southern California Population
Tripathi, M., Wong, A., Solomon, V. A., & Yassine, H. N. (2020) · Endocrine Practice · doi:10.4158/ep-2020-0135 · Cited by 9 · see citing works
Cheng, Y., Li, T., Tan, P., Du, Y., Huang, Z., Shi, H., Cai, T., Chen, Y., & Fu, W. (2022) · Endocrine · doi:10.1007/s12020-022-03025-8 · Cited by 9 · see citing works
Approach to the Adult Patient with Chylomicronemia
Hegele, R. A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf701 · Cited by 9 · see citing works
Peterson, A. L. H., Ashraf, A. P., Bachman, J., Hegele, R. A., Rashad, M., South, A. M., Tran, A. H., Zachariah, J. P. V., & Wong, J. P. (2026) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000195 · Cited by 8 · see citing works
Choi, J., Kim, H., Jun, J., Ryu, J. K., & Lee, H. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.62734 · Cited by 8 · see citing works
Childhood Hypertriglyceridemia: Is It Time for a New Approach?
Sunil, B., & Ashraf, A. P. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01000-2 · Cited by 8 · see citing works
Genetic Lipid Disorders Associated with Atherosclerotic Cardiovascular Disease
Mszar, R., Webb, G., Kulkarni, V., Ahmad, Z., & Soffer, D. E. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.11.009 · Cited by 8 · see citing works
Wilson, D. P., Williams, L. H., & Kavey, R.-E. W. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2021.12.017 · Cited by 7 · see citing works
Self-citationTransitional Medicine of Intractable Primary Dyslipidemias in Japan
Ogura, M., Okazaki, S., Okazaki, H., Tada, H., Dobashi, K., Nakamura, K., Matsunaga, K., Miida, T., Minamino, T., Yokoyama, S., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22016 · Cited by 6 · see citing works
Gouni‐Berthold, I. (2019) · Journal of the Endocrine Society · doi:10.1210/jendso/bvz035 · Cited by 6 · see citing works
Masson, W. M., Barbagelata, L., Fleitas, M., Herzkovich, N., Kerschner, E., Rossi, E., Siniawski, D. A., Ami, M. V., & Nogueira, J. P. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000601 · Cited by 5 · see citing works
Posicionamento Brasileiro sobre Síndrome da Quilomicronemia Familiar – 2023
Izar, M. C. D. O., Santos, R. D., Assad, M. H. V., Chagas, A. C. P., Toledo, A. D. O., Nogueira, A. C. C., Souto, A. C. C. F., Lottenberg, A. M., Chacra, A. P. M., Ferreira, C. E. D. S., et al. (2023) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20230203 · Cited by 7 · see citing works
Bardey, F., Rieck, L., Spira, D., März, W., Binner, P., Schwab, S. K., Kleber, M. E., Danyel, M., Barkowski, R., Bobbert, T., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100589 · Cited by 4 · see citing works
Xia, Y., Zheng, W., Du, T., Gong, Z., Liang, L., Wang, R., Yang, Y., Zhang, K., Lu, D., Chen, X., et al. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.09.012 · Cited by 4 · see citing works
Makhmudova, U., Schulze, P. C., Stefan Lorkowski, A., März, W., Geiling, J. A., & Weingärtner, O. (2024) · Journal of Medical Case Reports · doi:10.1186/s13256-024-04532-0 · Cited by 4 · see citing works
Diagnosis, Evaluation, and Management of Severe Hypertriglyceridemia
Krishnamurthy, A., Homan, E. A., & Kim, S. M. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00758-9 · Cited by 4 · see citing works
Giammanco, A., D’Erasmo, L., Iannuzzo, G., Noto, D., Montali, A., Zambon, A., Forte, F., Suppressa, P., Giannini, S., Barbagallo, C. M., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.10.073 · Cited by 3 · see citing works
Joubert, S., Ninan, J., Rosario, N., Davis, S. R., Wollen, J. T., & Wang, E. M. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00774-5 · Cited by 3 · see citing works
Heath, O., Allender, B., Smith, J. D., Savva, E., Spencer, L., Bannister, E. G., Brown, N. J., Evans, M. S., Kiss, S., Rozen, T. H., et al. (2024) · JIMD Reports · doi:10.1002/jmd2.12434 · Cited by 3 · see citing works
Long-Term Nutritional Counseling for a Patient with Lipoprotein Lipase Deficiency
Torii, T., Taniguchi-Fukatsu, A., Kawawaki, M., Shimoura, Y., & Ozaki, K. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63821 · Cited by 3 · see citing works
Fiber in the Treatment of Dyslipidemia in Pediatric Patients
Capra, M. E., Biasucci, G., Travaglia, E., Sodero, R., Banderali, G., & Pederiva, C. (2025) · Children · doi:10.3390/children12040427 · Cited by 3 · see citing works
Tratamiento de la quilomicronemia
Hermoso, A. N., & Valdivielso, P. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.01.004 · Cited by 3 · see citing works
Síndrome de quilomicronemia familiar: experiencia pediátrica en Argentina
Araújo, M. A. L., Eiberman, G. F., Etcheverry, N., & Pacheco, G. (2022) · Archivos Argentinos de Pediatria · doi:10.5546/aap.2022.e123 · Cited by 3 · see citing works
Shah, P., Sawhney, A., Anamika, F., Kanagala, S. G., Parikh, K., Mendpara, V. A., Garg, N., & Jain, R. (2023) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/0118715257267341231031120105 · Cited by 2 · see citing works
Theodoropoulos, P., Fanaropoulou, N. M., & Manessis, A. (2024) · AACE Clinical Case Reports · doi:10.1016/j.aace.2024.08.006 · Cited by 2 · see citing works
Kessler, A. S., Brown, T. M., Bratlee‐Whitaker, E., Fehnel, S. E., Vera‐Llonch, M., Arca, M., Averna, M. R., Baass, A. W., Baum, S. J., Bergeron, J., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.06.014 · Cited by 2 · see citing works
Bajaj, A., Oral, E. A., Brown, A. S., Gaudet, D., Alexander, V. J., Karwatowska‐Prokopczuk, E., & Baum, S. J. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101352 · Cited by 2 · see citing works
Gaudet, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00035-2 · Cited by 2 · see citing works
Salvatore, V., Gilstrap, A., Williams, K. R., Hsieh, A., Gwosdow, A. R., Stevenson, M. T., & Davidson, D. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.03.035 · Cited by 2 · see citing works
Medical Nutrition Therapy for Lipid and Lipoprotein Disorders
Sapp, P. A., Johnston, E. A., Petersen, K. H., Fleming, J. A., & Kris‐Etherton, P. M. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_9 · Cited by 2 · see citing works
Tünnemann-Tarr, A., Scharnagl, H., Katzmann, J. L., Stürzebecher, P. E., & Laufs, U. (2021) · Medicine · doi:10.1097/md.0000000000027573 · Cited by 2 · see citing works
Hypertriglyceridaemia: Contemporary management of a neglected cardiovascular risk factor
Khan, T. Z., Schatz, U., Bornstein, S. R., & Barbir, M. (2021) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2021.19 · Cited by 2 · see citing works
Lipids, Lipoproteins, and Cardiovascular Outcomes
Sakers, A. P., Mszar, R., & Soffer, D. E. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_9 · Cited by 1 · see citing works
Bubnova, M. G., Ezhov, M. V., Aronov, D. M., Galyаvich, A. S., Gurevich, V. S., Duplyakov, D. V., Zafiraki, V. K., Karamnova, N. S., Kashtalap, V. V., Konovalov, G. A., et al. (2025) · Cardiosomatics · doi:10.17816/cs688224 · Cited by 1 · see citing works
Meghashree, N., B, K. C., & Shivaraj, D. R. (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.1.72 · Cited by 1 · see citing works
The evaluation of plozasiran for the treatment of familial chylomicronemia syndrome
Hang, S., & Hegele, R. A. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2646166 · Cited by 1 · see citing works
Nutrition in Pediatric Patients and Vulnerable Populations: Updates and Advances
Grammatikopoulou, M. G., & Vassilakou, T. (2024) · Children · doi:10.3390/children11040430 · Cited by 1 · see citing works
Two Novel Mutations Associated with Familial Chylomicronemia in a Neonate
Jha, V. V., Arora, G., & Arora, V. (2024) · Newborn · doi:10.5005/jp-journals-11002-0105 · Cited by 1 · see citing works
Ueda, M. (2024) · Translational Pediatrics · doi:10.21037/tp-24-131 · Cited by 1 · see citing works
Dietary Interventions for Hypertriglyceridemia
Kirkpatrick, C. F., Petersen, K. S., Kris-Etherton, P. M., & Maki, K. C. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01444-w
Effective Treatment for Acute Pancreatitis Depends on Underlying Etiologies
Rhodes, K. S., Williams, L. H., Welstead, L. A., Karmally, W., Alexander, L., & Sutton, L. (2019) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2019.01.010
Self-citationFamilial Hyperlipidemia Type 1
Regmi, M. R., & Rehman, A. U. (2019) · StatPearls
Acute Pancreatitis After a Meatless Burger in Familial Chylomicronemia Syndrome
Haxhi, J., Bote, J., & Thompson, P. D. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.12.005
Familial chylomicronemia syndrome in children and adolescents: diagnosis and treatment
Pshenichnikova, I. I., Zakharova, I. N., Osmanov, I. M., Trunina, I. I., Pupykina, V. V., Arsel'gova, I. K.-B., Koba, Y. V., Bocharova, T. I., & Abazova, A. R. (2023) · Pediatrics Consilium Medicum · doi:10.26442/26586630.2022.4.201989
Síndrome de quilomicronemia: aspectos genéticos y revisión de la literatura
Ricardo Fuentes, U., & Rosa Pardo, V. (2022) · Revista Hospital Clínico Universidad de Chile · doi:10.5354/2735-7996.2022.68961 · Cited by 1 · see citing works
Approach to Hypertriglyceridemia
Hegele, R. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-24113-0_9
Dyslipidämien und Herz-Kreislauf-Erkrankungen
Stefan Lorkowski, A., & Kassner, U. (2023) · Elsevier eBooks · doi:10.1016/b978-3-437-23016-5.00016-7
Sotiriadis, D., & Patsatsi, A. (2023) · Springer eBooks · doi:10.1007/978-3-031-15130-9_106
[A case of neonatal-onset type I hyperlipoproteinemia with bloody ascites].
Chen, Y., Hu, L., Zhang, K., Zhang, X., Cao, Y., Yang, L., Wu, B., Zhou, W., & Wang, J. (2023) · PubMed Central · doi:10.7499/j.issn.1008-8830.2307113
Infant with severe hypertriglyceridemia: a case report of familial chylomicronemia syndrome
Rangel, J., Meireles, W. W. D. S., Leite, A. C., Medina, C. T. N., Cardoso, M. T. D. O., & Silva, R. (2024) · Residência Pediátrica · doi:10.25060/residpediatr-2024.v14n1-923
- Authors
- Williams, L., Rhodes, K. S., Karmally, W., Welstead, L. A., Alexander, L., & Sutton, L.
- Affiliations
- Cook Children's Medical Center (US)
- Michigan Medicine (US)
- Columbia University (US)
- University of Chicago (US)
- Jacksonville Center for Clinical Research (US)
- Corresponding author
- Williams, Lauren
- Venue
- Journal of Clinical Lipidology
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 12
- Issue
- 4
- Pages
- 908-919
- ISSN
- 1876-4789 (ISSN-L)
- 1933-2874
- OpenAlex
- W2802917102
- Semantic Scholar
- 586a80b6c372497b316fad44f6486f8338a7fdf7
- Cited by
- 125
- References
- 62
- Citations by year
- 2026: 15 · 2025: 23 · 2024: 22 · 2023: 19 · 2022: 12 · 2021: 13 · 2020: 9 · 2019: 8 · 2018: 4
- FWCI
- 6.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of clinical lipidology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Ionis Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Lymphatic Disorders and Treatments
- Health Sciences › Nursing › Nutrition and Dietetics › Clinical Nutrition and Gastroenterology
- Keywords
- familial chylomicronemia syndrome, lipoprotein lipase deficiency, very low-fat diet, nutritional therapy, dietary guidelines, hypertriglyceridemia, pancreatitis, essential fatty acids, medium-chain triglyceride oil, fat-soluble vitamins, carbohydrate intake, weight management, patient-centered care
- MeSH terms
- Energy Intake, Humans, Life Style, Hyperlipoproteinemia Type I, Longevity, Pancreatitis, Guidelines as Topic, Diet, Fat-Restricted, Nutrition Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-08.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-08.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review